Fundacion Instituto Valenciano De Oncologia — Clinical Trial Site

263 Registered trials

102 Currently recruiting

Organisation

Fundacion Instituto Valenciano De Oncologia

Location

Valencia, Spain

Identifier

ORG-100032608

Address

Calle Professor Beltran Baguena 8, 46009, Spain

Departments

#755; Oncología
034032: Oncología Médica
03411: Oncología
1202: Oncología
1218:Oncología Médica
1508: Oncology
3606; Oncología
7002: Oncology
7004:Oncología
7005: Oncología Médica
7007: Oncologia
7009: Oncología Médica
724006: Oncología
9408:Oncology
Análisis clínicos y microbiología
Bajo Unidad de Investigacion Clinica
Cirugía
Dermatology
Fundación Instituto Valenciano de Oncología
Hematology
Instituto Valenciano de Oncologia
Medical Oncology
Medical Oncology Department
N/A
Nuclear Medicine
Onccology
Oncología
Oncología Médica
Oncology
Oncology Deparmtent
Oncology Department
Oncology service
Servicio de Farmacia
Servicio de Oncología
Servicio de Oncología Médica
Servicio de Urologia
Unidad Investigacion Clinica
Urology
Urology-Oncology

Clinical trials at this site (263)

Search interface

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended

2024-512925-95-00 Advanced/Metastatic Breast Cancer 5 2025-05-16
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration-… Ended

2024-513968-25-00 Metastatic castration-resistant prostate cancer (mCRPC) 5 2025-04-28
A Multicenter, Open-Label, Single-Arm, Phase II Trial Exploring the Maintenance of Trastuzumab and Pertuzumab Following Trastuzumab Deruxtec… Ended

2023-507306-13-00 HER2-positive unresectable locally recurrent or metasta 4 2025-04-13
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended

2024-512998-27-00 Non-Small Cell Lung Cancer 5 2025-02-21
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women with Breast Cancer Who Are Having Hormone Therapy Ended

2024-510719-31-00 Moderate to Severe Vasomotor Symptoms (VMS) 5 2025-01-24
An open label, single-arm, phase 2 study of perioperative sacituzumab govitecan in combination with zimberelimab and domvanalimab for patien… Ended

2023-504420-26-00 Bladder Cancer 4 2025-01-13
Study to evaluate the use of durvalumab in combination with platinum-based chemotherapy followed by durvalumab with olaparib as first-line t… Ended

2024-514728-17-00 Advanced or recurrent endometrial cancer 11 2024-12-30
Sasanlimab Treatment As Bladder-Sparing Strategy For Patients With Muscle Invasive Bladder Cancer Ended

2024-511358-36-00 Molecularly Categorized Muscle Invasive Bladder Cancer 4 2024-11-11
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Rec… Ended

2023-505617-24-00 Recurrent Ovarian Cancer with High Folate Receptor-Alph 4 2024-11-05
A study to continue providing GME751 (a new medicine that is similar to pembrolizumab) to participants who are eligible for pembrolizumab tr… Ended

2024-513160-25-00 Melanoma and Non-small-cell lung cancer 5 2024-10-30
SPOTLIGHT 204: A Multicenter, Phase 2b, open-label, non-randomized, clinical trial to evaluate safety, tolerability and preliminary efficacy… Ended

2024-511801-51-00 Basal cell carcinoma 4 2024-10-24
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer Ended

2024-511038-11-00 advanced prostate cancer 4 2024-09-24
ELVN-002 combined with trastuzumab +/- chemotherapy in HER2 + Solid Tumors Ended

2023-509716-29-00 Solid Tumors, Colorectal Cancer and Breast Cancer 9 2024-09-23
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer (PolyDamas) Ended

2022-501452-29-00 Metastatic Non-small Cell Lung Cancer 9 2024-08-28
A study to learn the effects of ripretinib (study drug) on how midazolam behaves in the body of people with advanced gastrointestinal stroma… Ended

2022-501477-40-00 Advanced Gastrointestinal Stromal Tumor 3 2024-06-25
A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-sm… Ended

2023-508359-38-00 Early-stage Non-squamous Non-small Cell Lung Cancer 5 2024-06-05
A clinical trial to look at how ZN-A-1041 alone or ZN-A-1041 plus some approved drugs works to reduce tumor size and how safe these drugs ar… Ended

2023-508459-37-00 HER2-positive advanced solid tumours 1 2024-05-28
A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalim… Ended

2023-504598-18-00 Advanced solid tumors 1 2024-04-03
A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either… Ended

2023-503357-35-00 Non-small Cell Lung Cancer (NSCLC) 4 2024-03-20
MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer Ended

2023-504816-14-00 Endometrial cancer 5 2024-03-08
A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended

2023-503827-25-01 Non-Small Cell Lung Cancer (NSCLC) 5 2024-02-16
Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended

2023-503428-24-00 Neoplasms, Head and Neck 4 2024-01-19
DAREON™-8: A study to test how well different doses of BI 764532 in addition to standard of care are tolerated by people with advanced small… Ended

2023-506008-20-00 Extensive-stage small cell lung carcinoma (ES-SCLC) 3 2024-01-11
A trial to examine the biological effects of Saruparib (AZD5305) alone, Darolutamide alone, and in combination in patients with newly diagno… Ended

2023-503691-25-00 Newly diagnosed prostate cancer 3 2023-12-11